Market Data 
Markets
Replies to post #75086 on Biotech Values
03/27/09 6:34 AM
TEVA NVS MNTA: Based on the same principle, we can argue that if Teva loses, then the FDA should not approve Copaxone because a court has found that Novartis did not steal enough important data and hence the copy cannot be exact.
AI
